Filing Details

Accession Number:
0001567619-20-020096
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-19 16:16:59
Reporting Period:
2020-11-17
Accepted Time:
2020-11-19 16:16:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1512762 Coherus Biosciences Inc. CHRS Biological Products, (No Disgnostic Substances) (2836) 273615821
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1733375 R Vincent Anicetti Coherus Biosciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City CA 94065
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-17 2,500 $2.50 51,056 No 4 M Direct
Common Stock Disposition 2020-11-17 2,500 $17.50 48,556 No 4 S Direct
Common Stock Disposition 2020-11-17 12,420 $17.68 36,136 No 4 S Direct
Common Stock Disposition 2020-11-17 3,567 $17.68 32,569 No 4 S Direct
Common Stock Acquisiton 2020-11-18 4,283 $12.70 36,852 No 4 M Direct
Common Stock Disposition 2020-11-18 4,283 $18.00 32,569 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-11-17 2,500 $0.00 2,500 $2.50
Common Stock Stock Option (Right to Buy) Disposition 2020-11-18 4,283 $0.00 4,283 $12.70
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,488 2024-06-30 No 4 M Direct
22,500 2027-08-06 No 4 M Direct
Footnotes
  1. Includes 31,250 restricted stock units.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
  3. The transaction was executed in multiple trades in prices ranging from $17.27 to $17.85, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  4. The transaction was executed in multiple trades in prices ranging from $17.44 to $17.82, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  5. The transaction was executed in multiple trades in prices ranging from $17.46 to $17.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  6. All of the shares underlying this option are vested and exercisable as of the date hereof.